[HTML][HTML] PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases

HO Alsaab, FD Alharbi, AS Alhibs, NB Alanazi… - Pharmaceutics, 2022 - mdpi.com
Research on the use of biodegradable polymers for drug delivery has been ongoing since
they were first used as bioresorbable surgical devices in the 1980s. For tissue engineering …

[HTML][HTML] The tobacco smoke component, acrolein, as a major culprit in lung diseases and respiratory cancers: Molecular mechanisms of acrolein cytotoxic activity

P Hikisz, D Jacenik - Cells, 2023 - mdpi.com
Acrolein, a highly reactive unsaturated aldehyde, is a ubiquitous environmental pollutant
that seriously threatens human health and life. Due to its high reactivity, cytotoxicity and …

[HTML][HTML] Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary

A Agustí, BR Celli, GJ Criner, D Halpin… - American journal of …, 2023 - atsjournals.org
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published the
complete 2023 GOLD report, which can be freely downloaded from its web page (www …

Pulmonary rehabilitation for adults with chronic respiratory disease: an official American Thoracic Society clinical practice guideline

CL Rochester, JA Alison, B Carlin… - American journal of …, 2023 - atsjournals.org
Background: Despite the known benefits of pulmonary rehabilitation (PR) for patients with
chronic respiratory disease, this treatment is underused. Evidence-based guidelines should …

Global burden of chronic obstructive pulmonary disease through 2050

E Boers, M Barrett, JG Su, AV Benjafield… - JAMA Network …, 2023 - jamanetwork.com
Importance Chronic obstructive pulmonary disease (COPD) is a respiratory condition that is
associated with significant health and economic burden worldwide. Previous studies …

COPD and multimorbidity: recognising and addressing a syndemic occurrence

LM Fabbri, BR Celli, A Agustí, GJ Criner… - The Lancet …, 2023 - thelancet.com
Most patients with chronic obstructive pulmonary disease (COPD) have at least one
additional, clinically relevant chronic disease. Those with the most severe airflow obstruction …

[HTML][HTML] Pulmonary rehabilitation and physical interventions

T Troosters, W Janssens, H Demeyer… - European …, 2023 - Eur Respiratory Soc
Pulmonary rehabilitation has established a status of evidence-based therapy for patients
with symptomatic COPD in the stable phase and after acute exacerbations. Rehabilitation …

[HTML][HTML] Matrix metalloproteinases in chronic obstructive pulmonary disease

ME Christopoulou, E Papakonstantinou… - International Journal of …, 2023 - mdpi.com
Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade proteins of the
extracellular matrix and the basement membrane. Thus, these enzymes regulate airway …

Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled …

A Anzueto, IZ Barjaktarevic, TM Siler… - American Journal of …, 2023 - atsjournals.org
Rationale: Ensifentrine is a novel, selective, dual phosphodiesterase (PDE) 3 and PDE4
inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of …

Lung-function trajectories: relevance and implementation in clinical practice

E Melén, R Faner, JP Allinson, D Bui, A Bush… - The Lancet, 2024 - thelancet.com
Lung development starts in utero and continues during childhood through to adolescence,
reaching its peak in early adulthood. This growth is followed by gradual decline due to …